-
Paroxetine Mesylate: From SERT to Cancer Assays
2026-09-22
Paroxetine Mesylate is a Selective serotonin reuptake inhibitor whose research value extends from SERT pharmacology to MET–ERBB3 signaling in colorectal cancer models. This article explains how to interpret its concentration-dependent biology, salt-form identity, and multi-endpoint assay evidence without overextending preclinical findings.
-
Human PSC Teratomas Reveal Skeletal Myogenic Lineage
2026-09-22
Pappas and colleagues show that human pluripotent stem cell-derived teratomas generate multiple skeletal myogenic progenitor states that parallel stages of embryonic muscle development. Single-cell transcriptomics and surface-marker validation identify ERBB3 and CD82 as practical handles for enriching this lineage, providing a foundation for studying human muscle development and regenerative cell sourcing.
-
Abiraterone Acetate: CYP17 Inhibitor Research Guide
2026-09-21
Abiraterone acetate is a CYP17 inhibitor used to study androgen biosynthesis and prostate cancer biology. Its reported nanomolar potency, formulation constraints, and mixed performance in patient-derived spheroids define a research framework rather than a clinical treatment recommendation.
-
BMS-345541 in Notch/NF-κB Limb Ischemia Research
2026-09-21
The reference study shows that thymosin-β4 promotes endothelial activity and post-ischemic angiogenesis in critical limb ischemia through coordinated Notch/NF-κB signaling. Its use of DAPT and BMS pathway inhibition links molecular signaling changes with cell migration, tube formation, and vascular-marker expression, while also highlighting important limits of pharmacological pathway interpretation.
-
Sumatriptan Succinate for Translational Assays
2026-09-20
Sumatriptan Succinate can do more than model migraine biology: it supports receptor-resolved studies of CGRP release, inflammatory signaling, ischemia/reperfusion injury, and drug metabolism. This workflow-oriented guide shows how to choose concentrations, controls, endpoints, and troubleshooting strategies for reproducible serotonergic signaling research.
-
Tioconazole: Causal Assays for Fungal Biology
2026-09-19
Tioconazole is an antifungal medication for dissecting ergosterol-dependent fungal phenotypes. This article presents an assay-interpretation framework inspired by energy-sensitive DNA-repair research, helping distinguish target engagement, metabolic stress, and nonspecific loss of viability.
-
Topological Stress, rDNA Lesions, and PML Compartments
2026-09-18
Urbancokova and colleagues show that persistent damage in ribosomal DNA, rather than genotoxic stress in general, is a key trigger of PML-nucleolar associations. Their combination of chemical stress, targeted I-PpoI cleavage, repair-pathway perturbation, and lesion-state imaging provides a framework for studying how nucleolar DNA damage contributes to senescence and genome instability.
-
FH1 for iPS Hepatocyte Maturation
2026-09-18
FH1 is a research-use small molecule for improving the functional maturity of iPS cell-derived hepatocytes, with practical readouts spanning albumin, CYP3A4, AFP, and colony morphology. This workflow shows how to integrate FH1 into differentiation studies, liver cell transplantation research, and carefully controlled assays inspired by light-regulated gene expression.
-
Protoporphyrin IX: Heme and Photodynamic Biology
2026-09-17
Protoporphyrin IX is the final intermediate of heme biosynthesis and a photodynamic compound with applications in photodynamic cancer diagnosis and therapy research. Its iron-chelation chemistry, light-dependent reactivity, porphyria-related risks, and assay limitations require careful experimental interpretation.
-
FH1 and the Next Generation of Hepatocyte Models
2026-09-17
FH1 offers a practical route to more functional iPS-derived hepatocyte models by improving albumin secretion, CYP3A4 expression, colony morphology, and AFP performance. This thought-leadership article positions FH1 within a broader translational strategy that connects cell-state engineering with emerging, controllable gene-regulation technologies while clearly separating established evidence from future possibilities.
-
Patient-Derived 3D Spheroids in Prostate Cancer
2026-09-16
Linxweiler and colleagues established viable three-dimensional spheroid cultures from organ-confined prostate cancer tissue obtained during radical prostatectomy, creating a patient-derived model that retains key epithelial and androgen receptor features. The platform supported long-term culture, cryopreservation, immunophenotyping, and comparative drug testing, while also revealing important differences between androgen receptor antagonists, docetaxel, and abiraterone.
-
Oltipraz: Nrf2 and Phase II Enzyme Research
2026-09-16
Oltipraz is a small-molecule Nrf2 pathway activator and phase II enzyme inducer used in chemoprevention and toxicology research. Its reported GST and NQO1 induction provides a defined benchmark for studying oxidative-stress defense, while MASLD applications remain exploratory and require direct validation.
-
Cytoskeleton-Dependent Autophagy Under Compression
2026-09-15
The reference study shows that microfilaments are central to autophagy induced by compressive mechanical stress, while microtubules make a supporting contribution. By combining cytoskeletal perturbation with fluorescent imaging and western blotting, it provides a mechanistic framework for studying how cellular architecture converts force into autophagy signals.
-
Antimycin A4: Metabolic Assay Workflows
2026-09-15
Antimycin A4 links ATP-citrate lyase inhibition with mitochondrial respiratory-chain disruption, making it useful for separating lipid-biosynthesis effects from acute energy failure. This workflow-focused guide covers stock preparation, paired enzyme and cell assays, concentration planning, and troubleshooting for more interpretable metabolic data.
-
Y-27632 ROCK Inhibitor Workflow for YAP/TAZ Assays
2026-09-14
Y-27632 provides a reversible way to test how ROCK-dependent cytoskeletal remodeling influences stress fibers, cell shape, and anchorage-independent growth. This workflow connects practical dose design with the GPR35–Rho–YAP/TAZ findings reported in colorectal cancer models.